Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
about
The paradox role of caspase cascade in ionizing radiation therapyEvolving Therapies and FAK Inhibitors for the Treatment of CancerPTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.Screening of potential molecular targets for colorectal cancer therapy.TRAIL in cancer therapy: present and future challenges.Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 ExpressionCombination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.Targeted therapies for advanced Ewing sarcoma family of tumors.TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Combined modality therapy with TRAIL or agonistic death receptor antibodies.Emerging antibody combinations in oncology.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studiesBcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cellsEnhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.Targeting death receptors: is this trail still hot?Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapyImprovement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo.Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions.Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour
P2860
Q28079723-A40DA9F8-A9D2-436F-8250-EF0BA0EB4BEAQ28972291-E174D871-A08A-430D-BAA7-A4ECC53ED6F4Q31122542-FCCCBEF1-A64D-45CB-AD23-4148B3544D2FQ33288897-ECF90129-D040-42CA-9371-83181AAFDD8AQ33523440-A6E1F428-BA4E-4A2C-97CD-6AA94634DBF5Q33726537-3AFDF221-E12F-4CAF-B1CC-A66FA6BD50A4Q33735051-2DCD0B61-7DC3-4808-A976-8198AF1719ACQ34291312-7EC3F393-9F47-44CA-ABF7-B9FE6774FB1EQ34429203-38FA2FED-7C39-41A5-B59F-0A39770A00B0Q34464915-1727A7A9-0A34-484F-AFAF-D62190B05363Q35327231-8347C087-3A4B-44C7-8E4F-51505A16B9F1Q35589492-68E10D64-2B30-456B-899A-5758FFA6817AQ35681794-96C637EF-208E-4D10-9EF1-A1C26DB55906Q36259724-428F2BB9-F9A6-4BCD-A0CF-E7E19FEAE281Q36389203-E3576D4B-799A-4674-9B18-8FC5E6D99478Q36784690-85CADDCA-F506-46AC-A19D-ACFBDB454064Q37178718-1AD6A8A7-5832-4749-8A35-1EE72A48907AQ37602717-1C2658AE-4372-4CCE-B74B-E8D538A9151BQ37832083-DF546955-8631-44D2-BCF3-E2ED3DDB1A06Q37893414-D66BA10A-2F82-4A95-8643-E4D0CF98E767Q38115574-532DBBEA-0460-4CD5-AC27-19F196B48973Q39455419-39882BC2-7F51-442A-8AA7-D23C187BDFEDQ39963809-9C1F944D-994B-4898-A039-5EFA283FDB1FQ39983073-309ED6B6-5E1B-4904-B008-0F48E1724D7BQ40033141-363138D3-95B8-4E1F-B0BF-0F250D896667Q40609896-FF7C3A1C-FB30-4719-BF52-AF4B905B4056Q41483641-B2BC3B17-2087-4830-A958-4CF710A3FD3CQ42063450-86E8804D-658E-4C57-8D2E-B18326681046Q57174410-77F1B466-E522-4D55-A844-71FC6CB4FCDB
P2860
Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Combined treatment of colorect ...... ependent growth delay in vivo.
@ast
Combined treatment of colorect ...... ependent growth delay in vivo.
@en
type
label
Combined treatment of colorect ...... ependent growth delay in vivo.
@ast
Combined treatment of colorect ...... ependent growth delay in vivo.
@en
prefLabel
Combined treatment of colorect ...... ependent growth delay in vivo.
@ast
Combined treatment of colorect ...... ependent growth delay in vivo.
@en
P2093
P2860
P356
P1433
P1476
Combined treatment of colorect ...... ependent growth delay in vivo.
@en
P2093
Denzinger S
Humphreys R
Jendrossek V
Schiller D
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209516
P407
P577
2006-04-24T00:00:00Z
P5875
P6179
1026845491